Keyphrases
Advanced Colorectal Cancer
22%
Allogeneic
34%
Anti-PD-1 Therapy
22%
Antiretroviral Therapy
22%
CCL27
22%
CCL28
22%
CD137
34%
Cellular Immune Response
35%
Change Analysis
22%
Clinical Trials
22%
Disease-free Survival
22%
DNA Vaccine
32%
Dose Level
30%
Effector T Cells
34%
Epigenetic Modulators
22%
Guadecitabine
45%
Immune Response
22%
Interleukin-15 (IL-15)
22%
Intravenous Ascorbate
22%
Ipilimumab
22%
Irinotecan
54%
Lymphoid Aggregates
32%
Macaque
26%
Memory Subsets
22%
Metastatic Colorectal Cancer (mCRC)
45%
Metastatic Pancreatic Ductal Adenocarcinoma
59%
Microsatellite Stable
22%
Multi-omics Analysis
22%
Neoadjuvant
74%
Neoadjuvant Therapy
36%
Nivolumab
45%
Overall Survival
62%
Pancreatic Adenocarcinoma
22%
Pancreatic Cancer
26%
Pancreatic Ductal Adenocarcinoma
52%
Pancreatic Tumor
22%
Pembrolizumab
22%
Phase I Trial
45%
Phase II Study
45%
Plasmid
26%
Programmed Death-ligand 1 (PD-L1)
26%
Setpoint Following
22%
T Cells
34%
TAS-102
22%
Therapeutic Vaccine
30%
Trametinib
22%
Tumor Microenvironment
61%
Vaccine Response
33%
Viral Load
22%
Viral Replication
27%
Immunology and Microbiology
Adjuvant
6%
Adoptive Immunity
41%
Agonist
22%
Allele
18%
Antigen Specificity
16%
Arm
36%
CCL27
15%
CCL28
22%
CD4
7%
CD40 Ligand
13%
CD8
40%
Chemotaxis
5%
Cutaneous T Cell Attracting Chemokine
22%
Cyclophosphamide
16%
Cytotoxic T-Cell
33%
Disease Free Survival
18%
DNA Vaccine
48%
Effector Cell
7%
Granulocyte Macrophage Colony-Stimulating Factor
10%
Human Immunodeficiency Virus
29%
Human Immunodeficiency Virus 1
21%
Human Immunodeficiency Virus Antigen
22%
Immune Response
54%
Immunotherapy
36%
Interleukin 12
22%
Interleukin 15
45%
Low Drug Dose
16%
Lymphocyte
13%
Macaca
26%
Macaca fascicularis
22%
Major Histocompatibility Complex
13%
Monospecific Antibody
22%
Mouse
8%
Multi-Omics
22%
Neutrophil Granulocyte
11%
Nivolumab
42%
Overall Survival
44%
Plasmid
68%
Rhesus Monkey
45%
RNA Sequence
5%
Simian Immunodeficiency Virus
59%
T Cell
49%
T-Helper Cell
33%
Urelumab
9%
Vaccination Policy
27%
Vaccine Adjuvant
25%
Vaccine Efficacy
100%
Viral Load
36%
Viral Replication
32%
Volume
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Anemia
12%
Ascorbic Acid
22%
Azacitidine
5%
Biological Activity
22%
Chemotherapy
25%
Clinical Trial
26%
Colorectal Cancer
22%
Diarrhea
7%
Differential Scanning Calorimetry
15%
Differentiated Thyroid Cancer
22%
Disease
7%
DNA Methyltransferase
11%
Dynamic Light Scattering
7%
Fluorouracil
9%
Folinic Acid
9%
Fourier Transform Infrared Spectroscopy
15%
Gene Delivery
7%
Growth Factor
8%
Guadecitabine
45%
Histone Deacetylase
11%
Ipilimumab
22%
Irinotecan
54%
Malignant Neoplasm
26%
Metastatic Colorectal Cancer
45%
Mitogen Activated Protein Kinase Kinase Inhibitor
22%
Neoplasm
17%
Neutropenia
9%
Overall Survival
25%
Oxaliplatin
9%
Pancreas Adenocarcinoma
18%
Pancreas Cancer
22%
Pancreas Tumor
22%
Pazopanib
22%
Pembrolizumab
22%
Phase I Trials
22%
Preclinical Study
5%
Progression Free Survival
15%
Protein Tyrosine Kinase
22%
Protein Tyrosine Kinase Inhibitor
22%
Regorafenib
22%
Solid Malignant Neoplasm
22%
Thermal Exposure
7%
Thermostability
7%
Thrombocytopenia
5%
Trametinib
22%
Tumor Microenvironment
10%
Tumor Vaccine
22%
Urelumab
11%
Vasculotropin Receptor
22%